Silver Book Fact

It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.

Tapp, Robyn J., Jonathan E. Shaw, C. Alex Harper, Mazimilian P. de Courten, Beverley Balkau, Daniel J. McCarty, Hugh R. Taylor, Timothy A. Welborn, Paul Z. Zimmet; on behalf of the AusDiab Study Group. The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population. Diabetes Care. 2003; 26(6): 1731-1737. http://care.diabetesjournals.org/content/26/6/1731

Reference

Title
The Prevalence of and Factors Associated with Diabetic Retinopathy in the Australian Population
Publication
Diabetes Care
Publication Date
2003
Authors
Tapp, Robyn J., Jonathan E. Shaw, C. Alex Harper, Mazimilian P. de Courten, Beverley Balkau, Daniel J. McCarty, Hugh R. Taylor, Timothy A. Welborn, Paul Z. Zimmet; on behalf of the AusDiab Study Group.
Volume & Issue
Volume 26, Issue 6
Pages
1731-1737
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Multifoca electroretinogram (mFERG) measures show abnormal function of the retina early in–and even prior to–diabetic retinopathy onset and could enhance monitoring of the early stages of disease progression in individuals.  
  • Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients…  
  • After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus…  
  • Detection and treatment of proliferative diabetic eye disease and clincally significant macular edema with laser therapy can reduce severe vision loss progression by 50% to 60%  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.